Cartesian Therapeutics Inc (RNAC)

07:05 AM

Cartesian therapeutics CTO sells $649,029 in stock - Investing.com

07:05 AM

07:09 AM

Cartesian Therapeutics to Present Updated Data from Phase - GlobeNewswire

07:09 AM

05:23 AM

Timothy Springer Bought 4.9% More Shares In Cartesian Therapeutics - Simply Wall St

05:23 AM

Nov 19, 2024

Cartesian Therapeutics (NASDAQ:RNAC) Shares Gap UpWhat's Next? - MarketBeat

Nov 19, 2024

Nov 18, 2024

Cartesian Therapeutics executive sells $875,042 in stock By Investing.com - Investing.com Canada

Nov 18, 2024

Nov 18, 2024

Cartesian Therapeutics' chief medical officer sells shares worth $907,532 By Investing.com - Investing.com Canada

Nov 18, 2024

Nov 18, 2024

Cartesian therapeutics director Timothy Springer buys $7.37M in stock By Investing.com - Investing.com Nigeria

Nov 18, 2024

Nov 18, 2024

Cartesian therapeutics director Timothy Springer buys $7.37M in stock - Investing.com

Nov 18, 2024

Nov 18, 2024

Cartesian therapeutics CTO Metin Kurtoglu sells shares worth $1.44 million - Investing.com

Nov 18, 2024

Nov 18, 2024

Cartesian Therapeutics' chief medical officer sells shares worth $907,532 - Investing.com

Nov 18, 2024

Nov 18, 2024

Cartesian Therapeutics executive sells $875,042 in stock - Investing.com

Nov 18, 2024

Nov 17, 2024

Cartesian Therapeutics, Inc. (RNAC) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 17, 2024

Nov 14, 2024

Yale University's Strategic Bet on Cartesian Therapeutics Skyrockets in Q3 2024 - Yahoo Finance

Nov 14, 2024

Nov 13, 2024

Cartesian Therapeutics Reports Q3 2024 Financial Results - MSN

Nov 13, 2024

Nov 12, 2024

HC Wainwright Cuts Cartesian Therapeutics (NASDAQ:RNAC) Price Target to $41.00 - Defense World

Nov 12, 2024

Nov 11, 2024

Cartesian Therapeutics (NASDAQ:RNAC) & Rapport Therapeutics (NASDAQ:RAPP) Head to Head Comparison - Defense World

Nov 11, 2024

Nov 10, 2024

Cartesian Therapeutics: Uncertainty Remains (NASDAQ:RNAC) - Seeking Alpha

Nov 10, 2024

Nov 09, 2024

HC Wainwright Has Lowered Expectations for Cartesian Therapeutics (NASDAQ:RNAC) Stock Price - MarketBeat

Nov 09, 2024

Nov 09, 2024

Cartesian Therapeutics Inc (RNAC) Reports Q3 2024 EPS of $(1.13), Revenue of $387K, Missing Analyst Estimates - GuruFocus.com

Nov 09, 2024

Nov 08, 2024

Cartesian Therapeutics (NASDAQ:RNAC) Earns Buy Rating from Needham & Company LLC - MarketBeat

Nov 08, 2024

Nov 08, 2024

Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire

Nov 08, 2024

Nov 08, 2024

Cartesian Therapeutics Awards New Employee Stock Options at $19.11 Per Share | RNAC | RNAC Stock News - StockTitan

Nov 08, 2024

Nov 07, 2024

Cartesian Therapeutics Inc. (RNAC) Quarterly 10-Q Report - Quartz

Nov 07, 2024

Nov 07, 2024

Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times

Nov 07, 2024

Nov 05, 2024

Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting - GlobeNewswire

Nov 05, 2024

Nov 05, 2024

Cartesian's Novel mRNA CAR-T Therapy Data Selected for Major ASH Conference Spotlight | RNAC Stock News - StockTitan

Nov 05, 2024

Nov 04, 2024

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $43.00 Consensus Price Target from Analysts - Defense World

Nov 04, 2024

Nov 01, 2024

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Nov 01, 2024

Oct 26, 2024

Insiders of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) must be disappointed as stock fell 10% after recent purchases - Simply Wall St

Oct 26, 2024

Oct 18, 2024

Bullish Cartesian Therapeutics Insiders Loaded Up On US$5.18m Of Stock - Yahoo Finance

Oct 18, 2024

Oct 16, 2024

Multiple Myeloma Pipeline Insights and Analysis 2024: FDA Approvals and Key Companies involved by DelveInsight | Novartis, AbbVie, Pfizer, Cartesian Therapeutics, Rapa Therapeutics - Barchart

Oct 16, 2024

Oct 16, 2024

Needham & Company LLC Reaffirms Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat

Oct 16, 2024

Oct 15, 2024

RNACCartesian Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Oct 15, 2024

Oct 15, 2024

Cartesian Therapeutics Announces Presentation of Results - GlobeNewswire

Oct 15, 2024

Oct 15, 2024

Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting - StockTitan

Oct 15, 2024

Oct 13, 2024

Insider Buying Slows, but Not for These 7 Buyers - 24/7 Wall St.

Oct 13, 2024

Oct 11, 2024

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Position Reduced by Renaissance Technologies LLC - MarketBeat

Oct 11, 2024

Oct 09, 2024

30,038 Shares in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Purchased by Marshall Wace LLP - MarketBeat

Oct 09, 2024

Oct 06, 2024

Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last? - MSN

Oct 06, 2024

Oct 05, 2024

Cartesian therapeutics director Timothy Springer buys $4.29m in stock By Investing.com - Investing.com South Africa

Oct 05, 2024

Oct 04, 2024

Timothy A. Springer Acquires 80,301 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Stock - Defense World

Oct 04, 2024

Oct 04, 2024

Insider Buying: Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Director Acquires 5,514 Shares of Stock - MarketBeat

Oct 04, 2024

Oct 04, 2024

Cartesian therapeutics director Timothy Springer buys $4.29m in stock - Investing.com

Oct 04, 2024

Oct 04, 2024

Cartesian Therapeutics Inc [NASDAQ: RNAC] Sees Increase in Stock Value - Knox Daily

Oct 04, 2024

Oct 04, 2024

Cartesian Therapeutics Inc (RNAC) Stock: A Year of Highs and Lows - The InvestChronicle

Oct 04, 2024

Oct 04, 2024

Emcore Corp. [EMKR] Records 50-Day SMA of $1.18 - Knox Daily

Oct 04, 2024

Oct 03, 2024

Point72 DIFC Ltd Invests $47,000 in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Oct 03, 2024